AbelZeta to Present at the Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, December 27, 2023 – AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced that Tony (Bizuo) Liu, Chairman and CEO, will present an update on the Company at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
Live Presentation: January 10, 2024
Time: 8:00-8:25am PT
Location: Mission Bay (32nd Floor) The Westin, San Francisco
About AbelZeta Pharma, Inc.
AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body’s own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.
Forward-Looking Statements
Company Contact:
Sarah Kelly
Director of Communications
AbelZeta Pharma Inc.
Phone: +1 (240) 552 5870
Email: [email protected]